A glance at 2024 ESC Guidelines for elevated BP and hypertension management

A glance at 2024 ESC Guidelines for elevated BP and hypertension management:

What is new and How to implement?

New â€œElevated BPâ€ category

Benefit for the overlooked group under hypertension threshold

What's New: Elevated BP is defined as an office SBP/ DBP of 120â€“139/70â€“89 mmHg¹

WHY

â–¼ 11% CVD risk

HR=0.89 (95% CI 0.81-0.98)

Meta-analyses of RCTs: BP-lowering therapy is beneficial (major CVD events reduced by 11%; HR = 0.89 95% 0.81-0.98)

CLINICAL PRACTICE IMPLICATION

^{Class IIa, Level C}Screening for elevated BP and CVD risk assessment should be considered every 3 years ( <40yrs) or annually (>=40yrs and others).¹

^{Class I, Level A}Treatment initiation is suggested for a subgroup of elevated BP with increased risk of CVD.¹

New â€œSystolic BP Treatment Targetâ€

Stronger push for â€˜The lower the better, but within reason^â€™1,3

What's New: BP target for most HTN patients is now 120â€“129/70â€“79 mmHg¹

WHY

CLINICAL PRACTICE IMPLICATION

^{Class I, Level A}To optimize CVD risk reduction, target systolic BP at 120â€“129 mmHg in most adults, if well tolerated.¹

^{Class I, Level A}Reduce SBP As Low As Reasonably Achievable (ALARA) and personalize target, if optimal BP not possible^1-3

Pharmacological Interventions

Treatment should be intensive, effective and tolerable

TREATMENT THRESHOLD^1,3

Early pharmacological therapy initiation in
1. Subgroup of elevated BP (>=130/80 mmHg) with increased CVD risk.
2. Hypertension threshold (BP>=140/90 mmHg regardless of age)

TREATMENT STRATEGIES FOR PRACTICE

First-line recommended therapies:
Including the major first-line drug classes (ARB, CCB, diuretics) in the guidelines.¹

Single-Pill Combinations (SPC) for better adherence:
Aligning with guideline emphasis on simplifying regimens to achieve BP control.¹

Robust cardiorenal protection evidence:
Supported by extensive CV and renal clinical trials.^4-9

Abbreviations:
HTN, hypertension; BP, blood pressure; ESC, European Society of Cardiology

References:
1. McEvoy JW, et al. Eur Heart J. 2025;46(14):1300; 2. Cohen JB. Hypertension. 2025;82(1):11-13.; 3. McCarthy CP, et al. Hypertension . 2025;82(3):432-444. 4. Pfeffer MA, et al. N Engl J Med 2003; 349(20): 1893-1906. 5. Cohn JN, et al. N Engl J Med 2001; 345(23): 1667-1675. 6. Viberti G et al. Circulation 2002; 106(6): 672-678. 7. Julius S et al. Lancet 2004; 363(9426): 2022-2031. 8. The NAVIGATOR study group. N Engl J Med 2010; 362: 1477-90. 9. Mancia G et al. J Hypertens. 2013; 31: 1281-357

20 Pasir Panjang Road #10-25/28 Mapletree Business City (West Tower) Singapore 117439

Phone: +65 6722 6010

This email and content herein have come from Novartis or Novartis's nominated third party providers.
This email is confidential and intended solely for the use of the named recipient.

If you are not the intended recipient of this email, please be advised that you may not retain, use, copy, forward, distribute or place any reliance on any or all of the content herein.

Would you like to stop receiving these emails? Unsubscribe here

This content is not for local distribution. This should be modified to accommodate local guidance before local distribution.

FOR HEALTHCARE PROFESSIONALS ONLY

FA-11421275

×

Medical Information Request

Ask Speakers